Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
BACKGROUND: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response.
METHODS: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann-Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months.
RESULTS: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804-0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883-0.939; p < 0.01).
CONCLUSIONS: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Biomedicines - 11(2023), 2 vom: 02. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 28.02.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/biomedicines11020433 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353371092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353371092 | ||
| 003 | DE-627 | ||
| 005 | 20231226055833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biomedicines11020433 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353371092 | ||
| 035 | |a (NLM)36830969 | ||
| 035 | |a (PII)433 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Becciolini, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response | ||
| 520 | |a METHODS: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann-Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months | ||
| 520 | |a RESULTS: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804-0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883-0.939; p < 0.01) | ||
| 520 | |a CONCLUSIONS: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DAPSA | |
| 650 | 4 | |a apremilast | |
| 650 | 4 | |a psoriatic arthritis | |
| 700 | 1 | |a Parisi, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Del Medico, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Farina, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Visalli, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Molica Colella, Aldo Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Lumetti, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Caccavale, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Scolieri, Palma |e verfasserin |4 aut | |
| 700 | 1 | |a Andracco, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Girelli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Bravi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Colina, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Volpe, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Ianniello, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Ditto, Maria Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Nucera, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Franchina, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Platè, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Donato, Eleonora Di |e verfasserin |4 aut | |
| 700 | 1 | |a Amato, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardi, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a De Lucia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Molica Colella, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Santilli, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Mansueto, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrero, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetta, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Arrigoni, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Sandri, Gilda |e verfasserin |4 aut | |
| 700 | 1 | |a Bruzzese, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Paroli, Marino |e verfasserin |4 aut | |
| 700 | 1 | |a Fusaro, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Ariani, Alarico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicines |d 2013 |g 11(2023), 2 vom: 02. Feb. |w (DE-627)NLM268899797 |x 2227-9059 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:2 |g day:02 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biomedicines11020433 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 2 |b 02 |c 02 | ||